MX355126B - Compuestos neuroesteroides. - Google Patents

Compuestos neuroesteroides.

Info

Publication number
MX355126B
MX355126B MX2015008264A MX2015008264A MX355126B MX 355126 B MX355126 B MX 355126B MX 2015008264 A MX2015008264 A MX 2015008264A MX 2015008264 A MX2015008264 A MX 2015008264A MX 355126 B MX355126 B MX 355126B
Authority
MX
Mexico
Prior art keywords
disease
formula
compounds
apoptosis
present
Prior art date
Application number
MX2015008264A
Other languages
English (en)
Inventor
Gravanis Achilleas
Castanas Elias
Margioris Andreas
Charalambopoulos Ioannis
Avlonitis Nikolaos
Minas Vassilios
Tsatsanis Christos
Alexaki Vasileia-Ismini
N Alexis Michael
Remboutsika Eumorphia
Vergou Varvara
Neophytou Constantinos
Calogeropoulou Theodora
Original Assignee
Bionature E A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionature E A Ltd filed Critical Bionature E A Ltd
Publication of MX355126B publication Critical patent/MX355126B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere a derivados de neuroesteroides novedosos con propiedades anti-apoptóticas, neuroprotectoras y neurogénicas que actúan en el sistema nervioso así como también a métodos para hacer los mismos y sus aplicaciones en el tratamiento y/o prevención o mejoramiento de enfermedades neurodegenerativas relacionadas con la apoptosis neuronal o lesión neuronal o condiciones relacionadas con o resultantes de la apoptosis, que incluyen pero no están limitadas a la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, esclerosis múltiple y esclerosis lateral amiotrófica (ALS), degeneración y desprendimiento de retina, neuoropatía periférica causada por anormalidades genéticas, diabetes, poliomielitis, herpes, SIDA y quimioterapia, traumatismo cerebral o isquemia y apoplejía. Los compuestos activos se representan por la Fórmula (I): en donde R1, R2, R3, R4, R5, R6, R7, A, B, X, Y y Z son como se define en la descripción de la invención. La presente invención también incluye composiciones las cuales comprenden uno o más de los compuestos de la fórmula (I).
MX2015008264A 2007-06-20 2008-06-17 Compuestos neuroesteroides. MX355126B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0711948.0A GB0711948D0 (en) 2007-06-20 2007-06-20 Neurosteriod compounds
PCT/GB2008/002067 WO2008155534A2 (en) 2007-06-20 2008-06-17 Neurosteroid compounds

Publications (1)

Publication Number Publication Date
MX355126B true MX355126B (es) 2018-04-06

Family

ID=38352591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008264A MX355126B (es) 2007-06-20 2008-06-17 Compuestos neuroesteroides.
MX2009013189A MX2009013189A (es) 2007-06-20 2008-06-17 Compuestos neuroesteroides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009013189A MX2009013189A (es) 2007-06-20 2008-06-17 Compuestos neuroesteroides.

Country Status (14)

Country Link
US (1) US9777037B2 (es)
EP (1) EP2158209B1 (es)
JP (1) JP5698974B2 (es)
KR (1) KR101579323B1 (es)
CN (1) CN101784558B (es)
AU (1) AU2008265046C1 (es)
BR (1) BRPI0813735A2 (es)
CA (1) CA2691071C (es)
EA (1) EA018632B1 (es)
GB (1) GB0711948D0 (es)
IL (1) IL202223B (es)
MX (2) MX355126B (es)
WO (1) WO2008155534A2 (es)
ZA (1) ZA200908215B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120068026A (ko) 2009-09-11 2012-06-26 바이오네이처 이.에이. 리미티드 염증 및 자가면역 질환에 대한 스테로이드 화합물의 용도
CN101884638B (zh) 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
US9388210B2 (en) * 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2013043985A1 (en) * 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
WO2013056181A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN104736158A (zh) 2012-01-23 2015-06-24 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RU2667010C2 (ru) 2012-08-21 2018-09-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса
EP4335505A3 (en) 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
SI2935307T1 (en) 2012-12-18 2018-08-31 Washington University Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
EP3868382A1 (en) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3488852T3 (da) 2013-08-23 2021-02-01 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
RS58375B1 (sr) * 2014-01-29 2019-03-29 Umecrine Cognition Ab Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SI3206493T1 (sl) 2014-10-16 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
EP3206494A4 (en) 2014-10-16 2018-07-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
PL3224269T3 (pl) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6838074B2 (ja) 2016-03-08 2021-03-03 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
JP2022516986A (ja) * 2019-01-08 2022-03-03 成都康弘薬業集団股▲フン▼有限公司 ステロイド化合物、その使用、およびその調製方法
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos
RU2750639C1 (ru) * 2021-04-27 2021-06-30 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Замещенные спироандростен-17, 6'[1,3,4]тиадиазины, обладающие противовирусной активностью
CN115068681B (zh) * 2022-06-10 2023-06-13 中国人民解放军空军特色医学中心 一种具有骨细胞脱落功能的PNIPAAm-g-PDA修饰PCL骨支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3094521A (en) * 1961-07-25 1963-06-18 Merck & Co Inc Alkanoylthio and pyrazolo androstane derivatives
US3364207A (en) 1962-08-13 1968-01-16 Searle & Co Polyhydrospiro[estr/androst-4-ene-17, 2'-furan/pyran]-3-one and intermediates
US3300489A (en) * 1964-07-24 1967-01-24 Smith Kline French Lab Steroidal c-17 spirolactones and processes and intermediates used in the preparation thereof
US3320242A (en) * 1964-11-12 1967-05-16 Parke Davis & Co 17beta, 20-epoxy steroids and methods for their production
US3413288A (en) 1965-07-07 1968-11-26 Parke Davis & Co Process for the production of steroidal c-17 spirolactones
GB1089788A (en) * 1965-07-07 1967-11-08 Parke Davis & Co Process for the production of steroidal lactone compounds and intermediates thereof
US3364238A (en) * 1966-04-04 1968-01-16 Searle & Co 3-oxygenated spiro[androstene-17, 1'-cycloprop-2'-ene], 2', 3'-dihydro derivatives corresponding and intermediates thereto
US3365475A (en) * 1966-07-22 1968-01-23 Merck & Co Inc Process for the preparation of 17alpha-(3'-hydroxy-propyl)-4-androstene-3beta, 17beta-diol
DE2237143A1 (de) * 1972-07-28 1974-02-14 Hoechst Ag Verfahren zur herstellung von beta(3-keto-7alpha-acetylthio-17beta-hydroxy4-androsten-17alpha-yl)-propionsaeuregamma-lacton und dessen 1-dehydro-derivat
DE2349023A1 (de) * 1973-09-26 1975-04-10 Schering Ag Neue d-homo-steroide
US3939155A (en) * 1974-06-28 1976-02-17 G. D. Searle & Co. 4',5'-Dihydrospiro[androst/estr-4-ene-17,2'(3'H)-furan]3,4'-dione and congeners, and intermediates thereto
US4054563A (en) * 1975-04-25 1977-10-18 Ciba-Geigy Corporation Process for the manufacture of spiro compounds of the steroid series
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
EP1310258A1 (en) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors

Also Published As

Publication number Publication date
CA2691071A1 (en) 2008-12-24
WO2008155534A9 (en) 2009-12-03
EP2158209A2 (en) 2010-03-03
WO2008155534A3 (en) 2009-04-09
CN101784558B (zh) 2014-07-02
BRPI0813735A2 (pt) 2014-12-30
ZA200908215B (en) 2011-02-23
US9777037B2 (en) 2017-10-03
CA2691071C (en) 2016-06-07
KR20100040292A (ko) 2010-04-19
EP2158209B1 (en) 2019-02-27
MX2009013189A (es) 2010-04-09
JP5698974B2 (ja) 2015-04-08
JP2010530404A (ja) 2010-09-09
CN101784558A (zh) 2010-07-21
US20100234335A1 (en) 2010-09-16
GB0711948D0 (en) 2007-08-01
EA018632B1 (ru) 2013-09-30
WO2008155534A2 (en) 2008-12-24
AU2008265046B2 (en) 2014-07-17
AU2008265046C1 (en) 2018-08-16
EA201070027A1 (ru) 2010-06-30
IL202223A0 (en) 2010-06-16
IL202223B (en) 2018-06-28
KR101579323B1 (ko) 2015-12-21
AU2008265046A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
MX355126B (es) Compuestos neuroesteroides.
WO2018015573A3 (en) Trem2 cleavage modulators and uses thereof
PH12018502101A1 (en) Heterocyclic compound
MX2020007318A (es) Compuesto heterociclico.
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
MX2019006645A (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
CA2560580A1 (en) Imidazole compounds for inhibition of a.beta.-peptide production and for modulation of the notch signaling pathway
TW200745135A (en) Therapeutic agents
EA017914B8 (ru) 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
WO2009040331A3 (en) Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
MX2019002444A (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
TW200635589A (en) Therapeutic agents
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
IL179751A0 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
CO6270359A2 (es) Moduladores de piperidinil y piperazinil de y-secretasa
MX2014000113A (es) Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos.
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
WO2022246204A3 (en) Compounds for reducing ptbp1 expression
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders